Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab

J AAPOS. 2013 Jun;17(3):323-5. doi: 10.1016/j.jaapos.2013.01.004. Epub 2013 Apr 19.

Abstract

A 25-week postmenstrual age premature infant was treated with bilateral intravitreal bevacizumab for retinopathy of prematurity at 35 weeks' PMA. Postinjection, the retinal vessels progressed anteriorly within the retina. The patient presented 1 year after injection with bilateral exudative retinal detachments. The right eye was treated with intravitreal bevacizumab, laser ablation, and scleral buckling, resulting in resolution of the exudation and detachment. The left eye was treated with vitrectomy and lensectomy, but persistent exudation and detachment remained. This case demonstrates the rare complication of exudative retinal detachment in the setting of retinopathy of prematurity, which may become more common with increasing use of bevacizumab. Importantly, it also demonstrates the need not only for frequent examination after bevacizumab injection for retinopathy of prematurity but long-term follow-up as well, until either the retina is fully vascularized or peripheral ablation is performed.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Exudates and Transudates
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Laser Coagulation
  • Recurrence
  • Retinal Detachment / complications*
  • Retinal Detachment / diagnosis
  • Retinal Detachment / therapy
  • Retinal Vessels / pathology
  • Retinopathy of Prematurity / diagnosis
  • Retinopathy of Prematurity / etiology*
  • Retinopathy of Prematurity / therapy
  • Scleral Buckling
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitrectomy

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab